Litigation

Recent Posts

Watchdog Group Makes 2nd Push To Ban Diet Pill
Posted on 15 Apr 2011 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. - (AP) For the second time in five years, public health advocates are calling on the Food and Drug Administration to ban a fat-blocking drug sold over-the counter and via prescription, pointing to new reports of kidney stones and pancreatic... Read More

Tags: Pondimin , Wyeth , obesity , Food and Drug Administration , Darvon , Public Citizen , Alli , diet drugs , diet pill , Meridia , FDA , Orlistat , fen-phen , fenfluramine , Redux , Litigation , GlaxoSmithKline , Roche , Xenical

Negligent Design Claim Reinstated on Appeal In Diet Drug Death Case
Posted on 3 Aug 2010 by Michael Lefkowitz

PHILADELPHIA - (Mealey's) A claim for negligent design is not subsumed in Pennsylvania's prohibition on strict liability claims against pharmaceutical manufacturers, the state Superior Court ruled Aug. 2 in a case asserting that Wyeth's diet... Read More

Tags: negligent design , Wyeth , PPH , dexfenfluramine , tort , personal injury , Patsy Lance , diet drugs , Patsy Lance v. Wyeth , Redux , Litigation , lawsuit , Catherine Ruth Lance , primary pulmonary hypertension

Pa. Supreme Court Says Drug Companies Can Be Sued For Marketing Dangerous Drugs
Posted on 23 Jan 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) Pennsylvania law allows drug companies to be sued if they fail to stop marketing drugs known to be unreasonably harmful, and the manufacturers are not immune from being sued for damages for lack of due care, the Pennsylvania... Read More

Tags: et al. v. Wyeth , drugs , Pondimin , Wyeth , phentermine , PPH , diet drug , American Home Products Corp. , dexfenfluramine , Food and Drug Administration , Catherine Lance , marketing drugs , Pfizer , Pennsylvania Supreme Court , Patsy Lance , Pennsylvania , FDA , fen-phen , fenfluramine , National Childhood Vaccine Injury Act , Redux , Litigation , valvular heart disease , primary pulmonary hypertension